SKIP TO CONTENT
about abbott
contact
International | eng
Country Language
International | eng
Country Language

PressureWire™ X Guidewire

For Wireless Physiology

PressureWire X Guidewire
Evidence

Use Of Physiology Significantly Reduces Major Adverse Coronary Events

The recent CorMicA (Coronary Microvascular Angina) trial revealed that patients may benefit when coronary microvascular dysfunction (CMD) is accurately diagnosed and appropriately treated.1 Learn more about diagnosing and treating CMD.

RFR clinical evidence derives from assessing over 3,500 lesions in 2,000 patients, and much of that evidence is from ILUMIEN I + PREDICT, VALIDATE RFR, IRIS-FFR and RE-VALIDATE RFR.2-6

Fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) is supported by more than 600 published studies including the FAME clinical trials.7-9

When integrated into cardiac cath lab procedures, measurement of FFR has been shown to reduce the incidence of major adverse coronary events (MACE) in patients being treated for complex coronary artery disease.

The FAME study—evaluating complex lesions—examined FFR measured exclusively by the PressureWire™ Certus System. Results showed that compared to angiography alone, FFR:

  • Allows more accurate identification of hemodynamically relevant stenoses8
  • Reduces mortality and myocardial infarction by 34%7
  • Lowers procedure and 1-year follow-up costs by 14%10
  • Does not increase procedure time8
  • Decreases the amount of contrast agent used8

Precise measurement of intravascular diagnostics relies on the market-leading PressureWire™ X Guidewire that combines excellent maneuverability—even in tortuous vessels—and reliable readings11, all of which can ensure accurate information in the cath lab.

References

  1. Ford TJ, Stanley B, Sidik N, et al. 1-year outcomes of angina management guided by invasive coronary function testing (CorMicA). JACC Intv. 2020; 13:33-45.
  2. Jeremias A, et al. Resting full-cycle ratio (RFR): a novel physiologic index compared to Fractional Flow Reserve (FFR) in assessing the hemodynamic severity of a coronary stenosis: ILUMIEN I + PREDICT. EuroPCR 2018.
  3. Svanerud J, Ahn JM, Jeremias A, et al. Validation of a novel non-hyperaemic index of coronary artery stenosis severity: the Resting Full-cycle Ratio (VALIDATE RFR) study. EuroIntervention. 2018;14:806-814.
  4. Ahn JM, et al. IRIS FFR: prognostic performance of five resting pressure-derived indexes of coronary physiology. TCT 2018.
  5. Lee JM, Choi KH, Park J, et al. Physiological and clinical assessment of resting physiological indexes. Circulation. 2019;139.
  6. Kumar G, Desai R, Goreet A, et al. RE-VALIDATE: Real world validation of the non-hyperemic index of coronary artery stenosis severity: resting full-cycle ratio (RFR) - RE-VALIDATE RFR. CRT 2019.
  7. Pijls NH, Fearon WF, Tonino PA, et al. Fractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention in Patients with Multivessel Coronary Artery Disease. 2-Year Follow-Up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) Study. JACC. 2010; 56(3): 177-184.
  8. Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. New Engl J Med. 2009;360:213-224. doi: 10.1056/NEJMoa0807611.
  9. De Bruyne B, et al. Fractional flow reserve–guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11), 991–1001. doi: 10.1056/NEJMoa1205361.
  10. Fearon WF, Bornschein B, Tonino PA, et al. Economic Evaluation of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Multivessel Disease. Circulation. 2010; 122:2545-2550.
  11. Data on file at Abbott

MAT-2003659 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2023 Abbott. All Rights Reserved.

MAT-2001111 v5.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

MAT-2305078 v1.0